Related Experiment Video
Updated: May 5, 2026
High Content Screening in Neurodegenerative Diseases
Published on: January 6, 2012
Identification of selective inhibitors of cancer stem cells by high-throughput screening
Piyush B Gupta1,2, Tamer T Onder1,3, Guozhi Jiang1,2
1Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139.
Abstract:
Screens for agents that specifically kill epithelial cancer stem cells (CSCs) have not been possible due to the rarity of these cells within tumor cell populations and their relative instability in culture. We describe here an approach to screening for agents with epithelial CSC-specific toxicity. We implemented this method in a chemical screen and discovered compounds showing selective toxicity for breast CSCs. One compound, salinomycin, reduces the proportion of CSCs by >100-fold relative to paclitaxel, a commonly used breast cancer chemotherapeutic drug. Treatment of mice with salinomycin inhibits mammary tumor growth in vivo and induces increased epithelial differentiation of tumor cells. In addition, global gene expression analyses show that salinomycin treatment results in the loss of expression of breast CSC genes previously identified by analyses of breast tissues isolated directly from patients. This study demonstrates the ability to identify agents with specific toxicity for epithelial CSCs.
Insights
Researchers developed a new screening method to find drugs targeting rare cancer stem cells (CSCs). Salinomycin selectively kills breast CSCs, inhibiting tumor growth and altering gene expression, offering a promising new therapeutic strategy.
Area of Science:
- Oncology
- Stem Cell Biology
- Pharmacology
Background:
- Epithelial cancer stem cells (CSCs) are rare and unstable in culture, hindering drug screening.
- Targeting CSCs is crucial for effective cancer therapy and preventing relapse.
Purpose of the Study:
- To develop and implement a novel screening approach for identifying agents with specific toxicity against epithelial CSCs.
- To discover compounds selectively targeting breast CSCs.
Main Methods:
- Developed a new screening method for epithelial CSC-specific toxicity.
- Conducted a chemical screen using this method.
- Treated mice with identified compounds and analyzed tumor growth and differentiation.
- Performed global gene expression analyses.
Main Results:
- Discovered compounds with selective toxicity for breast CSCs.
- Salinomycin demonstrated >100-fold greater CSC reduction than paclitaxel.
- Salinomycin inhibited mammary tumor growth in vivo and increased epithelial differentiation.
- Salinomycin treatment led to the loss of key breast CSC gene expression.
Conclusions:
- The developed method enables effective screening for agents targeting epithelial CSCs.
- Salinomycin shows significant potential as a therapeutic agent against breast CSCs.
- This approach facilitates the identification of novel CSC-targeting drugs.
